Dr Paul Hutchison
National Party Associate Health Spokesman
10 November 2004
Pharmac review glosses over concerns
Pharmac's Annual Review, released today, glosses over significant concerns of the past year, says National's Associate
Health spokesman, Dr Paul Hutchison.
"The review might boast availability of some new drugs but, when it comes to choice, New Zealand's is not as good as
Australia's."
Dr Hutchison says Pharmac has served New Zealand very well in terms of keeping costs down, but the annual review ignores
a number of bad news stories.
* Tens of thousands of patients were forced to change their cholesterol-lowering medication and no safety
monitoring provisions were made for the switch. Pharmac and the Health Ministry could be accused of negligence for that
failure!
* Some terminally ill cancer patients were unable to access a morphine sulphate pain relief agent.
* Many drugs, such as the common anti-gout drug Allopurinol, have simply not been available. Pharmac's sole supply
policies are partly to blame.
* Pfizer Pharmaceuticals withdrew a grant of $65 million to New Zealand researchers. Pfizer said it was because it
could no longer have a sensible dialogue with Pharmac or the Government.
* The pharmaceutical budget's expenditure was downgraded from $566 million to $541 million in the past financial
year due to the delayed introduction of low drug co-payments from 1 October 2003 to 1 August 2004. The $25 million not
spent could have funded the breast cancer drugs Pharmac says it has no money for.
Dr Hutchison says National wants a full review of the agency because beneath the gloss there are some deep concerns.
Ends